Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy

Jacob T. Brown, Jeffrey R. Bishop, Katrin Sangkuhl, Erika L. Nurmi, Daniel J. Mueller, Jean C Dinh, Andrea Gaedigk, Teri E. Klein, Kelly E. Caudle, James T. McCracken, Jose de Leon, J.  Steven Leeder

Research output: Contribution to journalReview article

19 Scopus citations

Abstract

Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).

Original languageEnglish (US)
Pages (from-to)94-102
Number of pages9
JournalClinical pharmacology and therapeutics
Volume106
Issue number1
DOIs
StatePublished - Jul 2019

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Review

Fingerprint Dive into the research topics of 'Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy'. Together they form a unique fingerprint.

  • Cite this

    Brown, J. T., Bishop, J. R., Sangkuhl, K., Nurmi, E. L., Mueller, D. J., Dinh, JC., Gaedigk, A., Klein, T. E., Caudle, K. E., McCracken, J. T., de Leon, J., & Leeder, J. S. (2019). Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clinical pharmacology and therapeutics, 106(1), 94-102. https://doi.org/10.1002/cpt.1409